Caricamento...
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
For the past decade, docetaxel has remained the global standard of care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC). Until recently, there were limited options for patients with mCRPC following docetaxel failure or resistance, but now the approved treatment cho...
Salvato in:
| Pubblicato in: | Oncogene |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876694/ https://ncbi.nlm.nih.gov/pubmed/24276248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2013.497 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|